State Key Laboratory of Oncology in Southern China, Guanggzhou, PR China.
Radiat Oncol. 2013 Nov 13;8:265. doi: 10.1186/1748-717X-8-265.
N-stage is related to distant metastasis of nasopharyngeal carcinoma (NPC) patients. We performed this study to compare the efficacy of different chemotherapy sequences in advanced N-stage (N2 and N3) NPC patients treated with intensity modulated radiotherapy (IMRT).
From 2001 to 2008, 198 advanced N-stage NPC patients were retrospectively analyzed. Thirty-three patients received IMRT alone. Concurrent chemoradiotherapy (CCRT) was delivered to 72 patients, neoadjuvant chemotherapy (NACT) + CCRT to 82 patients and CCRT + adjuvant chemotherapy (AC) to 11 patients.
The 5-year overall survival rate, recurrence-free survival rate, distant metastasis-free survival rate and progress-free survival rate were 47.7% and 73.1%(p<0.001), 74.5% and 91.3% (p = 0.004), 49.2% and 68.5% (p = 0.018), 37.5% and 63.8% (p<0.001) in IMRT alone and chemoradiotherapy group. Subgroup analyses indicated that there were no significant differences among the survival curves of CCRT, NACT + CCRT and CCRT + AC groups. The survival benefit mainly came from CCRT. However, there was only an improvement attendency in distant metastasis-free survival rate of CCRT group (p = 0.107) when compared with RT alone group, and NACT + CCRT could significantly improve distant metastasis-free survival (p = 0.017).
For advanced N-stage NPC patients, NACT + CCRT might be a reasonable treatment strategy.
N 分期与鼻咽癌(NPC)患者的远处转移有关。我们进行这项研究是为了比较调强放疗(IMRT)治疗中晚期 N 分期(N2 和 N3)NPC 患者时,不同化疗顺序的疗效。
回顾性分析 2001 年至 2008 年收治的 198 例晚期 N 分期 NPC 患者。33 例患者接受单纯 IMRT,72 例患者接受同期放化疗(CCRT),82 例患者接受新辅助化疗(NACT)+CCRT,11 例患者接受 CCRT+辅助化疗(AC)。
单纯 IMRT 组和放化疗组的 5 年总生存率、无复发生存率、无远处转移生存率和无进展生存率分别为 47.7%和 73.1%(p<0.001)、74.5%和 91.3%(p=0.004)、49.2%和 68.5%(p=0.018)、37.5%和 63.8%(p<0.001)。亚组分析显示,CCRT、NACT+CCRT 和 CCRT+AC 组的生存曲线无显著差异。生存获益主要来自 CCRT,但与单纯 RT 组相比,CCRT 组仅显示出无远处转移生存率的改善趋势(p=0.107),而 NACT+CCRT 可显著提高无远处转移生存率(p=0.017)。
对于晚期 N 分期 NPC 患者,NACT+CCRT 可能是一种合理的治疗策略。